Table 8. Association of alleles combination with clinical variables of BC patients group.

Haplogenotype	Histological status	Clinical variable*	OR	95% (CI)	p-value
GGGGCC	Luminal A	Partial response	0.25	[0.07–0.07]	0.011
	HER2	Gastrict toxicity	0.21	[0.06–0.74]	0.016
GGGGTC	Triple negative	Stage I–II	0.3	[0.10–0.87]	0.044

Notes:

OR (odds ratio), CI (confidence intervals), p-value (significant <0.05).

^*Non-significance clinical variables included in the analysis: Age (<50, ≥50 years), tobacco and alcohol consumption, menopause, cancer type (ductal, lobular), Chemotherapy (non-chemotherapy response), non-chemotherapy response by recurrence. The non-response to chemotherapy treatment with Anthracyclines (e.g. doxorubicin, epirubicin, liposomal doxorubicin), taxanes (docetaxel, paclitaxel) and trastuzumab was evaluated according to the pathological Ryan’s classification described as follows: 1. Moderate response (single cells or small groups of cancerous cells), 2. Minimum response (residual cancer surrounded by fibrosis), and 3. Poor response (minimal or no tumor destruction, extensive residual cancer). Molecular classification (Luminal B).